Topic Paragraphs
FDA Broadens Access to Life-Saving Opioid Overdose Treatment Drug

FDA Broadens Access to Life-Saving Opioid Overdose Treatment Drug

The FDA has approved Rextovy (naloxone HCI) nasal spray 4 mg as an over-the-counter drug for the emergency treatment of opioid overdose. This action aligns with President Trump’s Great American Recovery Initiative, a federal effort to address the U.S.’ addiction and substance use disorder crisis and coordinate the government's approach to prevention, treatment, and long-term recovery.

Featured Topics

Recalls
Report a Problem
Warning Letters
Consumer Updates
483s
EUAs
510Ks
Guidance Documents
Drug Databases
Import Program

FDA in Action

Ensuring Quality and Access: FDA’s Approach to Generic Drug Oversight
Guidance shows how sponsors can build on existing science, reduce redundant testing and accelerate treatments
FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development
FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S.
FDA PreCheck Pilot Program Strengthens Domestic Pharmaceutical Manufacturing
Agency Unveils Real-Time Trial Proofs-of-Concept and Upcoming Pilot Program
FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA

Press Announcements

June 16, 2026

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

June 15, 2026

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes

June 12, 2026

FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children

Products We Regulate

Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood, and Biologics
Animal and Veterinary
Cosmetics
Tobacco Products
Back to Top